
About Crop Life Science
Crop Life Science is a publicly listed company based in Ahmedabad (India) founded in 2012. Insecticides, fungicides, herbicides, and plant health products are manufactured. The company has 194 employees. Its Indian entity Crop Life Science Limited reported revenue of βΉ209 Cr. Crop Life Science offers products and services including Insecticides, Fungicides, Herbicides, Micro Fertilizers, and Plant Growth Regulators. Its focus areas include Food and Agriculture, Crop Inputs and Diversified.
Company details
Crop Life Science was founded in 2012 in Ahmedabad, India, and operates in the agrochemical sector. Insecticides, fungicides, herbicides, micro fertilizers, plant growth regulators, and soil health products are produced. Technical-grade agrochemicals are manufactured at sites equipped with advanced technologies for quality control. A subsidiary is dedicated to packaging solutions, supporting overall operations in the plant health industry.
- Headquarters Ahmedabad, India
- Employees 194
- Stage Public
- SectorsAgriculture
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website croplifescience.com
- Social LinkedIn X Facebook
- Legal Name Crop Life Science Ltd.
- Market Cap₹162 Cr
CLSL-ST · NSE
- Share Price₹94.30
0.00% today
- Revenue₹207 Cr
FY 2025-26 · +3.3% YoY
- EBITDA₹17.77 Cr
Margin 8.6%
- Net Profit₹6.54 Cr
FY 2025-26 · +11.0% YoY
- P/E (TTM)24.7x
P/B 1.9x
- ROE8.0%
ROCE 11.1%
- Debt / Equity0.62
Interest cover 42.4x
- Employee Count194
Associated legal entities of Crop Life Science
Crop Life Science is associated with 2 registered companies on The Company Check; the primary company is Crop Life Science Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Crop Life Science Limited Listed CIN L24124GJ2006PLC048297 | Active | 24 May 2006 | Vadodara, Gujarat | ₹209 Cr | 182 | 8 | View details |
| Hetban Spechem Limited CIN U24120GJ2014PLC079146 | Active | 13 Mar 2014 | Vadodara, Gujarat | ₹1.0 Cr | 20 | 6 | View details |
Products & Services of Crop Life Science
Crop Life Science offers a comprehensive portfolio of products and services, including Insecticides, Fungicides, Herbicides, Micro Fertilizers, and Plant Growth Regulators.
Products for controlling insects in agricultural crops
Chemicals to manage fungal diseases in plants
Substances used for weed control in fields
Nutrient supplements to enhance soil fertility
Compounds to regulate and promote plant development
Items for improving overall soil and plant health
Board of directors of Crop Life Science Limited (Crop Life Science)
Crop Life Science Limited is the primary company behind Crop Life Science. The boards of the 2 registered companies of Crop Life Science currently have 10 directors; the longest-serving is Rajeshkumar Vrajlal Lunagariya, appointed in 2014. 24 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rajeshkumar Vrajlal Lunagariya DIN 01580748 | Director | 13 Mar 2014 | 12 yrs 8 mo | Hetban Spechem Limited, Crop Life Science Limited |
| Ashvinkumar Ravji Lunagaria DIN 02731913 | Director | 15 Jul 2014 | 12 yrs 4 mo | Hetban Spechem Limited, Crop Life Science Limited |
| Brajesh Lakhan Lal Kaithwas DIN 09255132 | Director | 28 Jul 2021 | 5 yrs 3 mo | Hetban Spechem Limited |
| Chunilal Samajubhai Virolia DIN 07984858 | Whole-time director | 10 Nov 2022 | 4 yrs | Crop Life Science Limited |
| Rajan Ashvinbhai Lunagariya DIN 10203025 | Director | 27 Nov 2024 | 1 yr 11 mo | Hetban Spechem Limited |
| Bansil Rajeshkumar Lunagariya DIN 08923739 | Director | 27 Nov 2024 | 1 yr 11 mo | Hetban Spechem Limited |
| Mansukh Amarshibhai Fultariya DIN 11023319 | Director | 28 Mar 2025 | 1 yr 7 mo | Hetban Spechem Limited |
| Sheetalben Rachit Shah DIN 11633798 | Director | 10 Apr 2026 | 7 mo | Crop Life Science Limited |
| Alpeshbhai Gordhanbhai Vaghasiya DIN 11746290 | Director | 30 Jul 2026 | 3 mo | Crop Life Science Limited |
| Pareshbhai Bhagvanbhai Parsana DIN 11758906 | Director | 30 Jul 2026 | 3 mo | Crop Life Science Limited |
IPO & Listings of Crop Life Science
Crop Life Science is a publicly listed company on the NSE with ticker symbol CLSL in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Aug 2023
- Listed onNSE: CLSL
- Listed entityCrop Life Science Ltd.
- Exchange sectorProcess industries
- ISININE00NH01017
- Share price₹61.70 (+4.93% on the day) · 2026-10-14
- Market capitalisation₹101 Cr
- Price to earnings15.9
- EPS (diluted, trailing year)₹3.87
- Volume (last session)2,000
Financials of Crop Life Science
Exchange-reported figures of Crop Life Science Limited, the listed company behind Crop Life Science (NSE: CLSL-ST).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 207 | 201 | 199 | 131 |
| Revenue growth | +3.3% | +1.0% | +51.3% | - |
| EBITDA | 17.77 | 16.34 | 12.62 | 11.79 |
| EBITDA margin | +8.6% | +8.2% | +6.4% | +9.0% |
| Profit before tax | 9.22 | 7.78 | 8.11 | 5.61 |
| Net profit | 6.54 | 5.89 | 5.67 | 4.08 |
| Net profit margin | +3.2% | +2.9% | +2.9% | +3.1% |
| EPS (βΉ) | 3.87 | 3.44 | 3.51 | 3.39 |
| Balance sheet | ||||
| Total assets | 146 | 127 | 112 | 68.03 |
| Net worth | 84.25 | 77.45 | 71.73 | 40.55 |
| Total debt | 56.57 | 44.31 | 35.40 | 26.99 |
| Cash & bank | 3.48 | 0.95 | 2.39 | 0.38 |
| Net working capital | 115 | 88.19 | 73.46 | 52.07 |
| Cash flow | ||||
| Cash from operations | (7.63) | (1.50) | (8.33) | 2.27 |
| Cash from investing | 1.58 | (4.11) | (3.42) | (4.48) |
| Cash from financing | (8.83) | (6.72) | 13.43 | 0.52 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 207 | 201 | 199 | 131 | 102 | 119 | 135 |
| Revenue growth | +3.3% | +1.0% | +51.3% | +28.6% | -14.2% | -12.0% | - |
| EBITDA | 16.97 | 15.89 | 12.63 | 11.78 | 7.71 | 8.73 | 8.26 |
| EBITDA margin | +8.2% | +7.9% | +6.4% | +9.0% | +7.6% | +7.3% | +6.1% |
| Profit before tax | 9.89 | 9.00 | 8.14 | 5.60 | 3.77 | 4.91 | 4.58 |
| Net profit | 6.89 | 6.62 | 5.69 | 4.07 | 2.78 | 3.64 | 3.22 |
| Net profit margin | +3.3% | +3.3% | +2.9% | +3.1% | +2.7% | +3.1% | +2.4% |
| EPS (βΉ) | 4.08 | 3.86 | 3.53 | 3.39 | 2.35 | 3.09 | 2.69 |
| Balance sheet | |||||||
| Total assets | 143 | 124 | 106 | 68.03 | 58.75 | 52.53 | 46.36 |
| Net worth | 85.35 | 78.20 | 71.74 | 40.55 | 36.02 | 33.15 | 29.70 |
| Total debt | 56.57 | 44.31 | 33.89 | 26.99 | 21.52 | 18.24 | 16.03 |
| Cash & bank | 2.93 | 0.73 | 0.58 | 0.38 | 2.07 | 3.09 | 2.31 |
| Net working capital | 113 | 87.40 | 71.17 | 52.07 | 45.60 | 39.46 | 34.37 |
| Cash flow | |||||||
| Cash from operations | (7.91) | (1.70) | (8.28) | 2.27 | (0.15) | 3.50 | 2.51 |
| Cash from investing | 1.53 | (3.83) | (15.89) | (4.48) | (1.99) | (2.15) | (0.74) |
| Cash from financing | (8.83) | (5.20) | 24.36 | 0.52 | 1.11 | (0.57) | (2.52) |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 207 | 201 | 199 | 131 |
| Revenue growth | +3.3% | +1.0% | +51.3% | - |
| Other income | 1.83 | 1.02 | 2.11 | 0.80 |
| Total expenses | 189 | 184 | 186 | 119 |
| Employee cost | 13.86 | 12.79 | 11.26 | 11.29 |
| EBITDA | 17.77 | 16.34 | 12.62 | 11.79 |
| EBITDA margin | +8.6% | +8.2% | +6.4% | +9.0% |
| Depreciation | 4.94 | 4.83 | 3.23 | 3.71 |
| Interest | 5.44 | 4.75 | 3.39 | 3.27 |
| Profit before tax | 9.22 | 7.78 | 8.11 | 5.61 |
| Tax | 2.74 | 2.19 | 2.09 | 1.53 |
| Net profit | 6.54 | 5.89 | 5.67 | 4.08 |
| Net profit margin | +3.2% | +2.9% | +2.9% | +3.1% |
| EPS (βΉ) | 3.87 | 3.44 | 3.51 | 3.39 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 17.14 | 17.14 | 17.14 | 12.00 |
| Reserves & surplus | 67.11 | 60.31 | 54.59 | 28.55 |
| Shareholders' funds (net worth) | 84.25 | 77.45 | 71.73 | 40.55 |
| Minority interest | 3.76 | 3.90 | 4.19 | 0.00 |
| Secured loans | 53.34 | 40.48 | 30.99 | 25.27 |
| Unsecured loans | 3.23 | 3.83 | 4.41 | 1.72 |
| Total debt | 56.57 | 44.31 | 35.40 | 26.99 |
| Total liabilities | 146 | 127 | 112 | 68.03 |
| Assets | ||||
| Gross block | 48.72 | 52.90 | 50.22 | 16.07 |
| Net block | 29.99 | 38.02 | 39.09 | 15.58 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.64 | 0.60 | 0.00 | 0.00 |
| Inventories | 70.56 | 48.89 | 39.82 | 26.19 |
| Sundry debtors | 74.14 | 69.29 | 77.26 | 32.56 |
| Cash & bank balances | 3.48 | 0.95 | 2.39 | 0.38 |
| Loans & advances | 28.48 | 23.05 | 20.51 | 26.43 |
| Total current assets | 177 | 142 | 140 | 85.56 |
| Total current liabilities | 61.72 | 53.99 | 66.52 | 33.49 |
| Net working capital | 115 | 88.19 | 73.46 | 52.07 |
| Total assets | 146 | 127 | 112 | 68.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | (34.24) | (21.92) | 0.72 | 2.07 |
| Net cash from operating activities | (7.63) | (1.50) | (8.33) | 2.27 |
| Net cash from investing activities | 1.58 | (4.11) | (3.42) | (4.48) |
| Net cash from financing activities | (8.83) | (6.72) | 13.43 | 0.52 |
| Net change in cash | (14.89) | (12.32) | 1.67 | (1.69) |
| Closing cash | 3.48 | 0.95 | 2.39 | 0.38 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | +3.3% | +1.0% | +51.3% | - |
| EBITDA growth | +8.8% | +29.5% | +7.0% | - |
| PBT growth | +18.5% | -4.1% | +44.6% | +9997.0% |
| Net income growth | +11.0% | +3.9% | +39.0% | - |
| Revenue CAGR (3Y) | +16.4% | - | - | - |
| EBITDA CAGR (3Y) | +14.7% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +3.1% | +2.8% | +3.0% | +3.1% |
| Return on capital employed | +11.1% | +10.9% | +13.1% | +13.0% |
| Return on net worth | +8.0% | +7.5% | +10.7% | +10.0% |
| Debt / equity | 0.62 | 0.53 | 0.56 | 0.67 |
| Long-term debt / equity | 0.06 | 0.10 | 0.14 | 0.16 |
| Interest cover | 42.40 | 41.27 | 36.10 | 40.47 |
| Efficiency & per share | ||||
| Fixed asset turnover | 4.08 | 3.89 | 5.99 | 8.17 |
| Inventory turnover | 3.47 | 4.52 | 6.02 | 5.01 |
| Debtors turnover | 2.89 | 2.74 | 3.62 | 4.03 |
| EPS (βΉ) | 3.87 | 3.44 | 3.51 | 3.39 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 49.15 | 45.19 | 41.85 | 33.80 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 207 | 201 | 199 | 131 | 102 | 119 | 135 |
| Revenue growth | +3.3% | +1.0% | +51.3% | +28.6% | -14.2% | -12.0% | - |
| Other income | 1.77 | 0.98 | 2.10 | 0.80 | 0.38 | 0.57 | 0.18 |
| Total expenses | 190 | 185 | 186 | 119 | 94.30 | 110 | 127 |
| Employee cost | 13.86 | 12.67 | 11.26 | 11.29 | 10.88 | 11.06 | 9.84 |
| EBITDA | 16.97 | 15.89 | 12.63 | 11.78 | 7.71 | 8.73 | 8.26 |
| EBITDA margin | +8.2% | +7.9% | +6.4% | +9.0% | +7.6% | +7.3% | +6.1% |
| Depreciation | 3.41 | 3.12 | 3.21 | 3.71 | 2.25 | 2.52 | 1.75 |
| Interest | 5.44 | 4.75 | 3.38 | 3.27 | 2.07 | 1.87 | 2.11 |
| Profit before tax | 9.89 | 9.00 | 8.14 | 5.60 | 3.77 | 4.91 | 4.58 |
| Tax | 2.92 | 2.38 | 2.09 | 1.53 | 0.96 | 1.23 | 1.36 |
| Net profit | 6.89 | 6.62 | 5.69 | 4.07 | 2.78 | 3.64 | 3.22 |
| Net profit margin | +3.3% | +3.3% | +2.9% | +3.1% | +2.7% | +3.1% | +2.4% |
| EPS (βΉ) | 4.08 | 3.86 | 3.53 | 3.39 | 2.35 | 3.09 | 2.69 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 17.14 | 17.14 | 17.14 | 12.00 | 12.00 | 12.00 | 12.00 |
| Reserves & surplus | 68.21 | 61.06 | 54.60 | 28.55 | 24.02 | 21.15 | 17.70 |
| Shareholders' funds (net worth) | 85.35 | 78.20 | 71.74 | 40.55 | 36.02 | 33.15 | 29.70 |
| Secured loans | 53.34 | 40.48 | 29.62 | 21.50 | 17.68 | 17.11 | 13.41 |
| Unsecured loans | 3.23 | 3.83 | 4.27 | 5.49 | 3.84 | 1.13 | 2.62 |
| Total debt | 56.57 | 44.31 | 33.89 | 26.99 | 21.52 | 18.24 | 16.03 |
| Total liabilities | 143 | 124 | 106 | 68.03 | 58.75 | 52.53 | 46.36 |
| Assets | |||||||
| Gross block | 27.84 | 32.02 | 29.64 | 23.21 | 15.15 | 16.45 | 13.54 |
| Net block | 15.64 | 22.14 | 21.83 | 15.58 | 11.23 | 12.87 | 12.01 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 1.45 | 0.00 | 0.00 |
| Investments | 13.12 | 13.08 | 12.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 70.56 | 48.89 | 39.82 | 26.19 | 22.26 | 29.37 | 23.00 |
| Sundry debtors | 74.14 | 69.29 | 77.40 | 32.56 | 36.86 | 26.09 | 27.43 |
| Cash & bank balances | 2.93 | 0.73 | 0.58 | 0.38 | 2.07 | 3.09 | 2.31 |
| Loans & advances | 27.99 | 22.53 | 19.27 | 26.43 | 20.24 | 14.53 | 11.34 |
| Total current assets | 176 | 141 | 137 | 85.56 | 81.43 | 73.08 | 64.08 |
| Total current liabilities | 62.31 | 54.04 | 65.90 | 33.49 | 35.83 | 33.62 | 29.71 |
| Net working capital | 113 | 87.40 | 71.17 | 52.07 | 45.60 | 39.46 | 34.37 |
| Total assets | 143 | 124 | 106 | 68.03 | 58.75 | 52.53 | 46.36 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | (34.26) | (23.53) | 0.38 | 2.07 | 3.09 | 2.31 | 3.05 |
| Net cash from operating activities | (7.91) | (1.70) | (8.28) | 2.27 | (0.15) | 3.50 | 2.51 |
| Net cash from investing activities | 1.53 | (3.83) | (15.89) | (4.48) | (1.99) | (2.15) | (0.74) |
| Net cash from financing activities | (8.83) | (5.20) | 24.36 | 0.52 | 1.11 | (0.57) | (2.52) |
| Net change in cash | (15.22) | (10.73) | 0.20 | (1.69) | (1.02) | 0.78 | (0.75) |
| Closing cash | 2.93 | 0.73 | 0.58 | 0.38 | 2.07 | 3.09 | 2.31 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +3.3% | +1.0% | +51.3% | +28.6% | -14.2% | -12.0% | - |
| EBITDA growth | +6.8% | +25.8% | +7.2% | +52.8% | -11.7% | +5.7% | - |
| PBT growth | +9.9% | +10.6% | +45.4% | +48.5% | -23.2% | +7.2% | +9997.0% |
| Net income growth | +4.1% | +16.3% | +39.8% | +46.4% | -23.6% | +13.0% | - |
| Revenue CAGR (3Y) | +16.4% | +25.3% | +18.6% | -1.0% | - | - | - |
| EBITDA CAGR (3Y) | +12.9% | +27.3% | +13.1% | +12.6% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +3.4% | +3.3% | +3.1% | +3.1% | +2.8% | +3.1% | +2.4% |
| Return on capital employed | +11.5% | +12.0% | +13.2% | +14.0% | +10.5% | +13.7% | +14.5% |
| Return on net worth | +8.6% | +8.8% | +10.8% | +10.6% | +8.1% | +11.8% | +10.9% |
| Debt / equity | 0.62 | 0.52 | 0.54 | 0.63 | 0.57 | 0.55 | 0.54 |
| Long-term debt / equity | 0.06 | 0.09 | 0.13 | 0.11 | 0.08 | 0.09 | 0.07 |
| Interest cover | 40.12 | 37.20 | 35.88 | 40.52 | 37.91 | 30.11 | 32.41 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 6.92 | 6.51 | 7.52 | 6.84 | 6.46 | 7.93 | 9.98 |
| Inventory turnover | 3.47 | 4.52 | 6.02 | 5.42 | 3.95 | 4.54 | 5.88 |
| Debtors turnover | 2.89 | 2.73 | 3.61 | 3.78 | 3.24 | 4.44 | 4.93 |
| EPS (βΉ) | 4.08 | 3.86 | 3.53 | 3.39 | 2.35 | 3.09 | 2.69 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 49.79 | 45.63 | 41.86 | 33.80 | 30.02 | 27.62 | 24.75 |
Web traffic of Crop Life Science
The website of Crop Life Science (croplifescience.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▲ 43.9% vs previous month
Websites whose visitors overlap most with Crop Life Science. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
indorama.in | indorama.in | 100% | #6,055,145 | β | |
| perfectcropscience.com | 98% | #13,226,259 | View details | ||
| zuari.in | 96% | 6.2K | #3,488,282 | View details | |
| agrocel.co.in | 96% | #6,443,997 | View details | ||
| shogunorganics.com | 95% | View details | |||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 21 similar websites and full traffic analytics for Crop Life Science
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Crop Inputs & Fertilizers
3 companies that operate in the same segment as Crop Life Science (Crop Inputs & Fertilizers) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of fertilizers, industrial chemicals, crop nutrition products, and real estate | 1979 | Pune, Maharashtra, India | USD 1.21 B | 1,020 | ||
Manufacturer of agrochemicals for crop protection | 1991 | Delhi, Delhi, India | USD 88.79 M | USD 222.96 M | 475 | |
Agrochemicals and equipment for crop protection are manufactured. | 1994 | Delhi, Delhi, India | USD 28.03 M | USD 303.27 M | 1,262 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Crop Life Science
Complete news archive for Crop Life Science
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Crop Life Science
Crop Life Science was founded in 2012.
Crop Life Science is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.
Crop Life Science has 194 employees.
The primary company behind Crop Life Science, Crop Life Science Limited, reported revenue of βΉ209 Cr for FY 2026, up 3% year on year.
Crop Life Science was founded in 2012 in Ahmedabad, India, and operates in the agrochemical sector. Insecticides, fungicides, herbicides, micro fertilizers, plant growth regulators, and soil health products are produced. Technical-grade agrochemicals are manufactured at sites equipped with advanced technologies for quality control. A subsidiary is dedicated to packaging solutions, supporting overall operations in the plant health industry.
Crop Life Science offers Insecticides, Fungicides, Herbicides, Micro Fertilizers, and 2 more products and services.
Yes, Crop Life Science is publicly traded on NSE under the ticker symbol CLSL.
Crop Life Science is associated with 2 legal entities: Crop Life Science Limited, Hetban Spechem Limited.
The legal entities of Crop Life Science currently have 11 directors, including Ashvinkumar Ravji Lunagaria, Rajan Ashvinbhai Lunagariya, Brajesh Lakhan Lal Kaithwas and others.
